Guardant Health, Inc. (BMV:GH)

Market Cap	217.62B
Revenue (ttm)	16.56B
Net Income (ttm)	-7.31B
Shares Out	n/a
EPS (ttm)	-58.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5
Average Volume	1,557
Open	1,150.00
Previous Close	820.00
Day's Range	1,150.00 - 1,150.00
52-Week Range	402.00 - 1,150.00
Beta	n/a
RSI	59.87
Earnings Date	Oct 29, 2025

About Guardant Health

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that p...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2011
• Employees: 2,021
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: GH

Financial Performance

In 2024, Guardant Health's revenue was $739.02 million, an increase of 31.04% compared to the previous year's $563.95 million. Losses were -$436.37 million, -8.98% less than in 2023.

Financial numbers in USD